The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs | Zendy

Christopher Mathew | Zendy; Alison A. Bettis | Zendy; Brian Chu | Zendy; Mike English | Zendy; Eric A. Ottesen | Zendy; Mark Bradley | Zendy; Hugo C. Turner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs

Author(s) -

Christopher Mathew,

Alison A. Bettis,

Brian Chu,

Mike English,

Eric A. Ottesen,

Mark Bradley,

Hugo C. Turner

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz671

Subject(s) - lymphatic filariasis , mass drug administration , medicine , administration (probate law) , food and drug administration , filariasis , drug , helminthiasis , drug administration , diethylcarbamazine , environmental health , intensive care medicine , immunology , pharmacology , helminths , population , political science , law

The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with the goal of eliminating lymphatic filariasis (LF) as a public health problem by 2020. Despite considerable progress, the current prevalence is around 60% of the 2000 figure, with the deadline looming a year away. Consequently, there is a continued need for investment in both the mass drug administration (MDA) and morbidity management programs, and this paper aims to demonstrate that need by estimating the health and economic burdens of LF prior to MDA programs starting in GPELF areas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research